These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2684517)

  • 1. Variations of recombinant human erythropoietin application in hemodialysis patients.
    Bommer J; Samtleben W; Koch KM; Baldamus CA; Grützmacher P; Scigalla P
    Contrib Nephrol; 1989; 76():149-56; discussion 156-8. PubMed ID: 2684517
    [No Abstract]   [Full Text] [Related]  

  • 2. Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. US multicenter trials.
    Sobota JT
    Contrib Nephrol; 1989; 76():166-78; discussion 212-8. PubMed ID: 2684519
    [No Abstract]   [Full Text] [Related]  

  • 3. Experience with daily self-administered subcutaneous erythropoietin.
    Granolleras C; Branger B; Beau MC; Deschodt G; Alsabadani B; Shaldon S
    Contrib Nephrol; 1989; 76():143-7; discussion 147-8. PubMed ID: 2684516
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy comparison of intravenous and subcutaneous recombinant human erythropoietin administration in hemodialysis patients.
    Bommer J; Barth HP; Zeier M; Mandelbaum A; Bommer G; Ritz E; Reichel H; Novack R
    Contrib Nephrol; 1991; 88():136-43. PubMed ID: 2040175
    [No Abstract]   [Full Text] [Related]  

  • 5. Understanding epoetin use: databases or clinical trials?
    Roger SD
    Nephrology (Carlton); 2007 Apr; 12(2):118-9. PubMed ID: 17371331
    [No Abstract]   [Full Text] [Related]  

  • 6. Once-weekly epoetin-beta in renal anemia: the clinical evidence.
    Albertazzi A
    Contrib Nephrol; 2002; (137):408-11. PubMed ID: 12101986
    [No Abstract]   [Full Text] [Related]  

  • 7. Randomized equivalence study evaluating the possibility of switching hemodialysis patients receiving subcutaneous human erythropoietin directly to intravenous darbepoetin alfa.
    Chazot C; Terrat JC; Dumoulin A; Ang KS; Gassia JP; Chedid K; Maurice F; Canaud B;
    Ann Pharmacother; 2009 Feb; 43(2):228-34. PubMed ID: 19407262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Advances in therapy of renal anemia: darbepoetin alfa].
    Schaefer R
    Wien Klin Wochenschr; 2002 Dec; 114(23-24):955-7. PubMed ID: 12635460
    [No Abstract]   [Full Text] [Related]  

  • 9. Erythropoietin therapy in chronic uremia: the impact of normalization of hematocrit.
    Murphy ST; Parfrey PS
    Curr Opin Nephrol Hypertens; 1999 Sep; 8(5):573-8. PubMed ID: 10541220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of intravenous, intraperitoneal, and subcutaneous recombinant erythropoietin in patients on CAPD. A rationale for treatment.
    Macdougall IC; Roberts DE; Neubert P; Dharmasena AD; Coles GA; Williams JD
    Contrib Nephrol; 1989; 76():112-20; discussion 120-1. PubMed ID: 2684515
    [No Abstract]   [Full Text] [Related]  

  • 11. Weekly subcutaneous erythropoietin maintains hematocrit in chronic hemodialysis patients.
    Parker KP; Sands JM
    J Am Soc Nephrol; 1993 Apr; 3(10):1717-8. PubMed ID: 8318688
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of the anemia of hemodialysis patients with recombinant human erythropoietin.
    Schaefer RM; Kuerner B; Zech M; Denninger G; Borneff C; Heidland A
    Int J Artif Organs; 1988 Jul; 11(4):249-54. PubMed ID: 3410565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of recombinant human erythropoietin (rh-EPO) in the treatment of anemia in hemodialysis patients: a multicenter Italian experience.
    Buccianti G; Colombi L; Battistel V
    Haematologica; 1993; 78(2):111-7. PubMed ID: 8349186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human erythropoietin in anemic patients on maintenance hemodialysis: comparison between intravenous and subcutaneous administration.
    Zehnder C; Blumberg A
    Nephron; 1991; 57(4):485-6. PubMed ID: 2046836
    [No Abstract]   [Full Text] [Related]  

  • 15. Hepatitis-associated improvement of anemia in an anephric patient without elevation of serum erythropoietin level.
    Navarro JF; Teruel JL; Villafruela JJ; Ortuño J
    Nephron; 1993; 65(3):495-6. PubMed ID: 8290014
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical effects of oral fluoxymesterone in patients with dialysis-controlled uremia.
    Lindholm DD; Fisher JW; Vieira JA; Dombeck DH; Bernal G; Lerthora J
    Trans Am Soc Artif Intern Organs; 1973; 19():475-83. PubMed ID: 4722764
    [No Abstract]   [Full Text] [Related]  

  • 17. A comparison of the responses to recombinant human erythropoietin in normal and uremic subjects.
    Eschbach JW; Haley NR; Egrie JC; Adamson JW
    Kidney Int; 1992 Aug; 42(2):407-16. PubMed ID: 1405323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of recombinant human erythropoietin treatment in end-stage renal failure patients. Results of a multicenter phase II/III study.
    Pollok M; Bommer J; Gurland HJ; Koch KM; Schoeppe W; Scigalla P; Baldamus CA
    Contrib Nephrol; 1989; 76():201-11; discussion 212-8. PubMed ID: 2684523
    [No Abstract]   [Full Text] [Related]  

  • 19. Correction of anemia using self-administered daily subcutaneous erythropoietin in uremic patients on continuous ambulatory peritoneal dialysis.
    Li PK; Leung CB; Lui SF; Leung JC; Shek AC; Lai KN
    Int J Artif Organs; 1993 Jul; 16(7):510-4. PubMed ID: 8370605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of recombinant human erythropoietin on hemostatic status in chronic uremic patients.
    Tsao CJ; Kao RH; Cheng TY; Huang CC; Chang SL; Lee FN
    Int J Hematol; 1992 Apr; 55(2):197-203. PubMed ID: 1511168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.